Esteve Invests Over $80 Million in China: Where CDMO Leaders and Investors Can Find the Next Opportunity

Spanish pharmaceutical company Esteve is investing more than $80 million to relocate, modernize, and expand its contract development and manufacturing organization (CDMO) operations in Shaoxing, China. The investment strengthens its Asian manufacturing network and increases its ability to produce complex small-molecule active pharmaceutical ingredients (APIs).

The expansion also reflects a wider industry trend. CDMOs are investing in specialized manufacturing capabilities, advanced technologies, and regional production networks to serve pharmaceutical and biotechnology companies developing increasingly complex medicines.

Download PDF Including Company Data, Master Dataset, Buyer Identification and More: https://www.towardshealthcare.com/download-sample/5034 

Esteve's China Investment: Key Details

Announced on October 21, 2026, the new Shaoxing facility strengthens Esteve's manufacturing presence in China after more than 20 years of operations in the country.

The facility combines three manufacturing workshops, automation, digitalization, and infrastructure designed to support further capacity expansion.

The expansion capacity matters because customers' manufacturing requirements can change as drug candidates progress from development to clinical trials and commercial production. Reserved infrastructure gives Esteve room to add capacity as customer needs evolve.

Why Esteve Is Expanding Across China and the US

Esteve is building a manufacturing network that can support customers across multiple development stages and regions.

In September 2026, the company announced an additional $17.5 million investment at its Morton Grove facility, bringing its total announced investment there to $33 million. The expansion includes two new 500-gallon reactors, improved containment capabilities for early-stage development, and warehouse upgrades.

The US site combines process research and development, analytical and stability testing, current good manufacturing practice (cGMP) API production, and chemistry, manufacturing, and controls (CMC) support. This allows customers to progress from early development toward larger manufacturing requirements.

For pharmaceutical buyers, regional manufacturing options can support supply planning and access to specialized technical capabilities. For Esteve, the two investments strengthen its ability to serve customers in Asia and North America through a broader manufacturing network.

Competitors Are Investing in Specialized Manufacturing

Esteve is not the only CDMO expanding its technical capabilities. Other providers are investing in areas that require specialized processes, equipment, and quality controls.

Lonza: Antibody-drug conjugates

In June 2026, Lonza announced an expansion of payload-linker manufacturing capacity at its Visp site in Switzerland. The project targets highly potent active pharmaceutical ingredients and antibody-drug conjugate (ADC) manufacturing, with commercial-scale capabilities expected in 2028.

ADCs combine antibodies with potent drug payloads. Their production requires specialized chemistry, purification, containment, and analytical capabilities. Lonza's investment targets these specific manufacturing requirements.

Catalent and Ori Biotech: Cell therapy manufacturing

On October 6, 2026, Catalent joined Ori Biotech's Preferred Partner Network. Catalent's Princeton, New Jersey facility will become a center of excellence for Ori's IRO platform, supporting autologous cell therapy process development and GMP manufacturing.

The collaboration gives therapy developers access to automated, closed manufacturing workflows designed to improve process consistency and scalability.

These investments highlight three distinct areas of competition: small-molecule APIs, complex ADC manufacturing, and advanced cell therapy production. CDMO buyers need different capabilities depending on the molecule, production process, development stage, and commercial requirements.

Where Are the Business Opportunities?

The expansion announcements identify several areas that pharmaceutical suppliers, technology providers, investors, and CDMOs can evaluate.

Specialized API manufacturing: Companies developing complex small molecules may require advanced synthesis, containment, purification, and process-development capabilities. Suppliers that solve a specific technical challenge can explore partnerships with established CDMOs.

High-potency manufacturing: Lonza's investment in ADC payload-linker capacity highlights the importance of handling highly potent compounds. Opportunities include specialized containment equipment, analytical services, process technologies, and supporting infrastructure.

Automated cell therapy production: Catalent's partnership with Ori Biotech demonstrates a model in which a CDMO combines its manufacturing expertise with an external technology platform. Technology developers can explore similar collaborations rather than building every capability independently.

Regional manufacturing networks: Esteve's investments in China and the US demonstrate the value of serving customers through multiple locations. CDMOs can assess regional capacity requirements, technical specialization, customer proximity, and supply-chain considerations before committing capital.

However, announced investments do not establish the size of an unmet-demand opportunity by themselves. Investors should validate customer demand, existing capacity, project economics, regulatory requirements, and likely facility utilization before making investment decisions.

How Towards Healthcare Supports CDMO Strategy

Towards Healthcare helps pharmaceutical and biotechnology decision-makers evaluate manufacturing opportunities, competitive positioning, and potential business partners through:

• Competitive Quadrants: Compare CDMO capabilities, manufacturing specializations, geographic presence, and competitive positioning.

• Pipeline Intelligence: Track emerging therapies and identify the manufacturing capabilities their development stages may require.

• Customized Dashboards: Monitor facility expansions, capital investments, partnerships, and manufacturing developments.

• Buyer Identification: Identify pharmaceutical and biotechnology companies that may need API development, specialized manufacturing, or outsourced production services.

The objective is to connect investment announcements with actionable business intelligence: which companies are expanding, which capabilities they offer, and where potential customers may need manufacturing support.

About Us

Healthcare WebWire is powered by Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium